Impact of glaucoma medication on ocular tissue

References

• Quigley HA. Number of people with glaucoma worldwide. Br. J. Ophthalmol.80(5), 389–393 (1996).
   PubMed Web of Science ®Google Scholar
• Lindblom B, Nordmann JP, Sellem E et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol. Scand.84, 74–83 (2006).
   PubMedGoogle Scholar
• Terminology and Guidelines for Glaucoma (3rd Edition). European Glaucoma Society, Dogma, Savova, Italy, 122–126 (2008).
   Google Scholar
• Terminology and Guidelines for Glaucoma (3rd Edition). European Glaucoma Society, Dogma, Savova, Italy, 127–137 (2008).
   Google Scholar
• Schein OD, Hibberd PL, Starck T et al. Microbial contamination of in-use ocular medications. Arch. Ophthalmol.110, 82–85 (1992).
   PubMedGoogle Scholar
• Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology99, 1082–1088 (1992).
   PubMed Web of Science ®Google Scholar
• Yalvaç IS, Gedikoğlu G, Karagöz Y et al. Effect of antiglaucoma drugs on ocular surface. Acta Ophthalmol. Scand.73, 248–256 (1995).
   Google Scholar
• Derous D, De Keizer W, De Wolff-Rouendall D, Soudjin W. Conjunctival keratinisation, an abnormal reaction to an ocular β-blocker. Acta Ophthalmol. Scand.67, 333–338 (1989).
   Google Scholar
• Wilson FM. Adverse external ocular effects of topical ophthalmicmedications. Surv. Ophthalmol.24, 57–88 (1979).
   PubMed Web of Science ®Google Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev. Ophthalmol.4(1), 59–64 (2009).
   Google Scholar
• De Saint Jean M, Brignole F, Bringuier AF et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci.40, 619–630 (1999).
   PubMed Web of Science ®Google Scholar
• Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr. Opin. Ophthalmol.18, 134–139 (2007).
   PubMed Web of Science ®Google Scholar
• Debbasch C, De Saint JM, Pisella PJ et al. Quaternary ammonium cytotoxicity in a human conjunctival cell line. J. Fr. Ophthalmol.22, 950–958 (1999).
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Fillacier K et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Human and animal studies. Ophthalmology106, 556–563 (1999).
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Fillacier K, Elena PP et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res.32, 3–8 (2000).
   PubMed Web of Science ®Google Scholar
• Champeau EJ, Edelhauser HF. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: The Preocular Tear Film in Health, Disease, and Contact Lens Wear. Holly F, Lamberts D, Mac Keen D (Eds). Dry Eye Institute Inc, TX, USA, 292–302 (1998).
   Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br. J. Ophthalmol.86, 418–423 (2002).
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol.17, 341–349 (2007).
   PubMed Web of Science ®Google Scholar
• Kuppens EVMJ, de Jong CA, Stolwijk TR et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br. J. Ophthalmol.79, 339–342 (1995).
   PubMed Web of Science ®Google Scholar
• McCulley JP, Shine WE. The lipid layer of tears: dependent on meibomian gland function. Exp. Eye Res.78, 361–365 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans. Ophthalmol. Soc. UK104, 402–409 (1985).
   PubMedGoogle Scholar
• Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol.82, 39–42 (1998).
   PubMed Web of Science ®Google Scholar
• Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin. Ophthalmol.3, 291–295 (2009).
   PubMedGoogle Scholar
• Rolando M, Brezzo V, Giordano G. In: Symposium on the Lacrimal System – Singapore 1990. van Bijsterveld OP, Lemp MA, Spinelli D (Eds). Kugler & Ghedini, Amsterdam, The Netherlands, 87–91 (1991).
   Google Scholar
• Arici MK, Arici DS, Topalkara A, Güler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin. Experiment. Ophthalmol.28(2), 113–117 (2000).
   PubMed Web of Science ®Google Scholar
• Lemp MA, Holly FJ, Iwata S, Dohlman CH. The precorneal tear film. I. Factors in spreading and maintaining a continuous tear film over the corneal surface. Arch. Ophthalmol.83(1), 89–94 (1970).
   PubMed Web of Science ®Google Scholar
• Paulsen F, Langer G, Hoffmann W, Berry M. Human lacrimal gland mucins. Cell Tissue Res.316, 167–177 (2004).
   PubMed Web of Science ®Google Scholar
• No authors listed. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul. Surf.5(2), 179–193 (2007).
   PubMed Web of Science ®Google Scholar
• Furrer P, Berger J, Mayer JM, Gurny R. A comparative study of the ocular tolerance of three timolol-based preparations: the influence of preservatives on ocular tolerance. J. Fr. Ophtalmol.24, 13–19 (2001).
   PubMed Web of Science ®Google Scholar
• Baudouin C. The pathology of dry eye. Surv. Ophthalmol.45(2), 211–220 (2001).
   PubMed Web of Science ®Google Scholar
• Martone G, Frezzotti P, Tosi GM et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am. J. Ophthalmol.147, 725–735 (2009).
   PubMed Web of Science ®Google Scholar
• Costagliola C, Prete AD, Incorvaia C et al. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch. Clin. Exp. Ophthalmol.239, 809–814 (2001).
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Debbasch C, Hamard P et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci.45, 1360–1368 (2004).
   PubMed Web of Science ®Google Scholar
• Baudouin C, Hamard P, Liang H et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the longterm. Ophthalmology111, 2186–2192 (2004).
   PubMed Web of Science ®Google Scholar
• Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp. Eye Res.49, 1–12 (1989).
   PubMed Web of Science ®Google Scholar
• Grant RL, Acosta D. Prolonged adverse effects of benzalkonium chlorideand sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. Fundam. Appl. Toxicol.33, 71–82 (1996).
   PubMedGoogle Scholar
• De Jong C, Stolwijk T, Kuppens E et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol.232, 221–224 (1994).
   PubMed Web of Science ®Google Scholar
• Dormans JA, Van Logten MJ. The effects of ophthalmic preservatives on corneal epithelium of the rabbit: a scanning electron microscopical study. Toxicol. Appl. Pharmacol.62, 251–261 (1982).
   PubMed Web of Science ®Google Scholar
• Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch. Clin. Exp. Ophthalmol.232, 561–565 (1994).
   PubMed Web of Science ®Google Scholar
• Brandt JD, Wittpen JR, Katz LJ et al. Conjunctival impression cytology in patients with glaucoma using long term topical medication. Am. J. Ophthalmol.112, 297–301 (1991).
   PubMed Web of Science ®Google Scholar
• Becquet F, Goldschild M, Moldovan MS et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr. Eye Res.17, 419–425 (1998).
   PubMed Web of Science ®Google Scholar
• Williams DE, Nguyen KD, Shapourifar-Tehrani S et al. Effects of timolol, betaxolol, and levobunolol on human Tenon’s fibroblasts in tissue culture. Invest. Ophthalmol. Vis. Sci.33, 2233–2241 (1992).
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology96, 327–335 (1989).
   PubMed Web of Science ®Google Scholar
• Baun O, Heegaard S, Kessing SV, Prause JU. The morphology of conjunctiva after long term topical anti-glaucoma treatment. Acta Ophthalmol. Scand.73, 242–245 (1995).
   PubMedGoogle Scholar
• Baudouin C, Liang H, Hamard P et al. The ocular surface of glaucoma patients treated over the longterm expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology115, 109–115 (2008).
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv. Ther.26(10), 970–975 (2009).
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O’Brien C et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol.112, 1437–1445 (1994).
   PubMed Web of Science ®Google Scholar
• Hamard P, Debbasch C, Blondin C et al. Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative. J. Fr. Ophtalmol.25, 777–784 (2002).
   PubMed Web of Science ®Google Scholar
• Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch. Ophthalmol.121, 835–839 (2003).
   PubMed Web of Science ®Google Scholar
• Shaffer RN, Rosenthal G. Comparison of cataract incidence in normal and glaucomatous population. Am. J. Ophthalmol.69(3), 368–370 (1970).
   PubMedGoogle Scholar
• Bernth-Petersen P, Bach E. Epidemiologic aspects of cataract surgery. III: Frequencies of diabetes and glaucoma in a cataract population. Acta Ophthalmol.61(3), 406–416 (1983).
   Web of Science ®Google Scholar
• Harding JJ, Egerton M, van Heyningen R, Harding RS. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br. J. Ophthalmol.77, 2–6 (1993).
   PubMed Web of Science ®Google Scholar
• Leske MC, Wu SY, Nemesure B, Hennis A. Barbados Eye Studies Group. Risk factors for incident nuclear opacities. Ophthalmology109, 1303–1308 (2002).
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.120, 1268–1279 (2002).
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressure. Am. J. Ophthalmol.126, 487–497 (1998).
   PubMed Web of Science ®Google Scholar
• Chandrasekaran S, Cumming RG, Rochtchina E, Mitchell P. Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract: the Blue Mountains Eye Study. Ophthalmology113, 417–424 (2006).
   PubMed Web of Science ®Google Scholar
• Herman DC, Gordon MO, Beiser JA et al. Topical ocular hypotensive medication and lens opacification: evidence from the Ocular Hypertension Treatment Study. Am. J. Ophthalmol.142, 800–810 (2006).
   PubMed Web of Science ®Google Scholar
• Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood–aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch. Ophthalmol.117, 34–40 (1999).
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv. Ophthalmol.47(1), 203–218 (2002).
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N, Goto Y et al. ESCRS Binkhorst Lecture 2002. Pseudophakic preservative maculopathy. J. Cataract Refract. Surg.29, 1800–1810 (2003).
   PubMed Web of Science ®Google Scholar
• Ardjomand N, Eckhardt M, Berghold A et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye14, 375–383 (2000).
   PubMed Web of Science ®Google Scholar
• Cellini M, Caramazza R, Bonsanto D et al. Prostaglandin analogs and blood–aqueous barrier integrity: a flare cell meter study. Ophthalmologica218, 312–317 (2004).
   PubMed Web of Science ®Google Scholar
• Chou A, Hori S, Takase M. Ocular toxicity of β-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies. Jpn J. Ophthalmol.29, 13–23 (1985).
   PubMed Web of Science ®Google Scholar
• Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch. Ophthalmol.108, 1543–1548 (1990).
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O’Brien C et al. Adverse effect of antiglaucoma medication: II. The outcome of filtration surgery. Arch. Ophthalmol.112, 1446–1454 (1994).
   PubMed Web of Science ®Google Scholar
• Young TL, Higginbotham EJ, Zou X, Farber MD. Effect of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology97, 1423–1427 (1990).
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, Stürmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch. Ophthalmol.114, 262–267 (1996).
   PubMedGoogle Scholar
• Baudolin C, Nordmann JP, Denis P et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch. Clin. Exp. Ophthalmol.240, 929–935 (2002).
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma17(5), 350–355 (2008).
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr. Opin. Ophthalmol.15, 132–135 (2004).
   PubMedGoogle Scholar
• Baudolin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol.86, 716–726 (2008).
   PubMed Web of Science ®Google Scholar
• Brasnu E, Brignole-Baudouin F, Riancho L et al.In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr. Eye Res.33(4), 303–312 (2008).
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea23(5), 490–496 (2004).
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv. Ther.25, 743–751 (2008).
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker R. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea27(3), 339–343 (2008).
   PubMed Web of Science ®Google Scholar
• Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv. Ophthalmol.32, 149–170 (1987).
   PubMed Web of Science ®Google Scholar